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Abstract
Background: The presence of ERα is the basis for treating breast cancer patients with targeted
molecular therapies that block estrogen stimulation of breast cancer cell division. To select patients
for the above therapies, currently, the ERα presence in breast cancer tissues is determined in
clinical laboratories by microscopically scoring the slides subjected to immunohistochemistry
(IHC). This method is not quantitative, highly subjective and requires large amount of tumor tissue,
therefore, cannot be applied to sterotactic and ultrasound guided biopsy samples. To circumvent
these problems, we previously developed quantitative real-time PCR based molecular assay that
can be applied to determine mRNA copies of ERα in picogram amounts of total RNA from tumor
samples. However, it is not known how the mRNA copy numbers correlate to IHC positive and
negative status.
Methods: In the current study we determined the copy numbers of ERα mRNA by Q RTPCR in
breast cancer tissues that were graded as ERα-positive and negative by 1) IHC and 2) functional
estrogen binding assay and statistically analyzed the data.
Results: We demonstrate here that ERα mRNA copy numbers are not significantly different in
tissues that are graded as positive by IHC and ligand binding assays. We establish here a cut of value
of 5 × 106 copies per 1010 mRNA copies of GAPDH with an Odds Radio of 39.4, Sensitivity of 0.81
and Specificity of 0.90 in breast cancer tissues that are negative for ERα protein by IHC and
estrogen binding assays. ROC analysis of the data gave an area of 0.8967 under the curve.
Conclusion: We expect that the cut off values determined here will be highly significant for
applying molecular assay in the place of IHC in clinical laboratories for evaluating the presence of
ERα for prognostic and therapeutic purposes.
Background
Breast cancer is the most diagnosed and the second lead-
ing cause of cancer deaths for women in the United States
striking about 300,000 and killing about 40,000 women
a year [1]. A substantial body of epidemiological, experi-
mental and clinical evidence indicated that unopposed
stimulation of breast epithelial cells by the natural hor-
mone, estrogen, plays a major role in the progression of
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breast cancers [2]. Because endogenous estrogens directly
promote the growth of breast cancer cells, estrogen depri-
vation either by inhibiting its biosynthesis (aromatase
inhibitors) or blocking estrogen-mediated gene transcrip-
tion (tamoxifen) through its high affinity receptor, the
estrogen receptor alpha (ERα), are the primary lines of
therapy for breast cancer patients. In most cases, the effi-
cacy of the above treatments has correlated with the pres-
ence of ERα in the tumor tissues. Currently, only those
patients who express ERα in their tumors are chosen for
aromatase inhibitor or tamoxifen therapies. In addition to
being a therapeutic target, ERα was also shown to be the
most important factor to predict breast cancer prognosis.
The patients who express ERα in their tumors have an
overall longer cancer-free survival and lower recurrence
rates than patients who do not express this receptor [3].
To predict prognosis and identify patients for the above
two anti-estrogen therapies, every breast cancer tissue is
currently screened for the presence of ERα before a treat-
ment regimen is selected for any breast cancer patient. The
presence of ERα in breast tumors was originally deter-
mined in clinical labs by estrogen binding assay for about
20 years. However, when the tumors were detected at
comparatively smaller sizes and highly specific mono-
clonal antibodies were developed that could detect ERα
both in the fresh frozen as well as formalin fixed paraffin-
embedded tissues, the clinical labs switched to immuno-
histochemistry (IHC) from estrogen binding assay for
determining the presence of ERα. Currently ERα is deter-
mined in the clinical laboratories from rough estimates
yielded by microscopically scoring the slides subjected to
IHC technique using antibodies against the N-terminal A/
B region of ERα. Although this procedure is used for over
ten years, it has several limitations including not quanti-
tative, highly subjective, variations due to antibody prep-
arations, variations from one clinical lab to other and
comparatively large sample size requirement.
In recent times, due to increased awareness and substan-
tially improved screening methods, breast cancers are
detected at very early stages and excised, in a large major-
ity of cases, by stereotactic and ultrasound guided tech-
niques. In these cases the limited amount of tumor tissue
that remains after histological testing restricts determining
ERα status for prognostic and therapeutic purposes by
IHC. In many cases, ERα status is not determined due to
insufficient amount of tumor tissue. For these reasons
there is an urgent need to switch to a procedure that can
detect ERα in a very small amount of tumor tissue
obtained by the above methods. There is a general consen-
sus that ERα mRNA quantification is a more suited tech-
nique for detecting its presence in tumor tissues. Several
PCR based approaches have been described for detecting
the presence of ERα in breast cancer tissues [4,5]. We
recently developed a highly sensitive real-time PCR based
quantitative molecular assay that can detect and quantify
as low as 50–100 copies of ERα mRNA from as small as
40 picograms of total RNA from breast cancer tissues.
Because quantitative real-time PCR is a high through-put
method, it could be automated to apply in clinical labora-
tories. However, it is not known how the ERα mRNA copy
numbers correlate to ERα positivity and negativity by IHC
assay. Establishing a cut off value in IHC negative tissues
is required for the application of molecular assay in the
place of IHC assay. To determine the cut off value, we have
profiled ERα mRNA copy numbers in breast cancer tissues
which have been graded as ERα positive and negative by
IHC and estrogen binding assays. We demonstrate here
that ERα mRNA copy numbers are not significantly differ-
ent in tissues that were graded as positive by IHC and lig-
and binding assays. However, ERα positive tissues, either
by IHC or estrogen binding assays, express significantly
higher mRNA copy numbers than the negative tissues. We
have determined the cut off values of ERα mRNA copy
numbers by molecular assay that correlate to ERα negativ-
ity by both IHC and ligand binding assays using CART
program (Classification And Regression Tree). We expect
that the cut off values determined here will be highly sig-
nificant for applying molecular assay in the place of IHC
in clinical laboratories for determining the ERα status for
prognostic and therapeutic purposes.
Methods
All the primers used in the current study were synthesized
by Gibco-BRL Life Technologies. TaqMan Universal PCR
Master Mix (Cat # 4304437) was from Applied Biosys-
tems. 5'FAM and 3'TAMARA labeled oligonucleotide
probes were synthesized by Applied Biosystems and avail-
able from previous studies. PCR quality water and Tris-
EDTA buffer were from BioWhittaker.
Breast tumor samples
Breast cancer tissues with known ERα status by IHC and
ligand binding assay were available from previous studies
[6-9]. Briefly, the tumor samples were collected from
either biopsy or mastectomies immediately after surgery
and stored at -80°C until use. Fresh tumor tissue samples
for ERα quantification were routinely harvested immedi-
ately adjacent to the histologic/diagnostic sections and
considered to be representative of the tissue used for diag-
nosis. All the samples were examined by a pathologist and
tissues containing > 80% cancer cells were excised and
used for ERα mRNA quantification. The ERα-status for the
samples used in this study was determined either by IHC
using monoclonal antibodies against NH2-terminal por-
tion of the molecule at Oncotech Laboratories, Irwine,
CA, or by ligand binding assay as described [10]. The
tumor tissues were considered positive for ERα by IHC if
> 5% of cancer cells showed positive nuclear staining. TheBMC Cancer 2007, 7:56 http://www.biomedcentral.com/1471-2407/7/56
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tumor tissues that were diagnosed as ERα positive by
estrogen binding assay had > 3 fmol of ER/mg of total tis-
sue extract. A total of 70 samples positive by IHC, 33 pos-
itive by estrogen binding assay, 43 negative by IHC and 20
negative by estrogen binding assay were included in the
current study (Tables 1, 2, 3 and 4 respectively). The
tumor tissues were processed to isolate total RNA and
cDNAs prepared as previously described [6-9]. Howard
University Institutional Review Board granted the ethical
approval of Tumor collection procedures for the study.
Absolute quantification of ERα mRNA copy numbers by 
quantitative real-time PCR
Absolute quantification of ERα transcript copy numbers
was achieved by quantitative real-time PCR in ABI Prism
GeneAmp 7900 HT Sequence Detection System as
described previously (9). Briefly, a typical real-time PCR
reaction mixture contained cDNA prepared from reverse
transcription of 0.5 – 5 nanograms of tumor tissue total
RNA, 0.04 micromolar each of sense and anti-sense prim-
ers, 0.05 micromolar 5'FAM and 3'TAMARA labeled oligo-
nucleotide probe and 1 × Taqman Universal PCR Mix in a
total volume of 25 μl. PCR conditions were initial hold at
50°C for two minutes, followed by denaturation for ten
minutes at 95°C, and denaturation for 15 seconds at
95°C in the subsequent cycles and annealing and exten-
sion for 1 min at 60°C for 40 cycles. The ERα mRNA copy
numbers in tumor tissues were determined in comparison
with a standard graph constructed simultaneously using
102, 103, 104, 105, 106, 107, 108, and 109 copies of reverse
transcribed cRNA of ERα. All the samples were amplified
in triplicate and real-time PCRs were repeated four times.
The ERα mRNA copy numbers in tumor tissues were nor-
malized to mRNA copy numbers of the house keeping
gene, glyceraldehyde 3- phosphate dehydrogenase
(GAPDH). GAPDH copy numbers were determined as
previously described [11,12]. The sense, and anti-sense
primers and probe for quantifying the mRNA copy num-
bers of ERα were 5' caagcccgctcatgatcaa 3' (position, exon
4, bp 1110–1128), 5'ctgatcatggagggtcaaatccac3' (position,
exon 5, bp 1358–1338) and FAM
5'agaacagcctggccttgtccctg3'TAMARA (position, exon 4, bp
1140–1162) respectively. The sense and anti-sense prim-
ers and probe for quantifying GAPDH mRNA copy num-
bers were 5'ttccagg agcgag atccct3' (position, bp 304–
322), 5'ggctgttgtcatacttctcatgg3' (position, bp 483–505)
and FAM 5' tgctggcgctgagtacgtcgtg3' TAMARA (position,
bp 342–363) respectively. Primer positions of ERα and
GAPDH nucleotide sequences were as described [13,14].
Statistical analysis
Wilcoxon-rank-sum test and standard two-sample t-test
were used to determine whether the mRNA copy numbers
were significantly different in breast cancer tissues that
were 1) ERα-positive and ERα-negative by IHC, 2) ERα-
positive and ERα-negative by estrogen binding assays, 3)
ERα positive by IHC and estrogen binding assays, and 4)
ERα-negative by IHC and estrogen binding assays. Test
results were considered significant if P ≤ 0. 05. To deter-
mine the cut-off value/maximum level of mRNA copy
numbers in the samples which were negative by IHC and
estrogen binding assays, we used CART (Classification
Regression Tree) [15,16] program. The data consisting of
103 ERα positive and 63 ERα negative samples which had
a predictive variable, mRNA copy numbers, were parti-
tioned into two groups using CART program. This pro-
gram determines the best cut-off value copy numbers in
the sense that the OR (Odds Ratio, ERα positive to ERα
negative in our case) of the two groups (with copy
number greater than the cut-off value in one group and
less or equal to the cut-off value in the other) is maxi-
mized. Receiver Operating Characteristic (ROC) analysis
was performed to determine the sensitivity and specificity
of the RNA based molecular assay. The ROC curves were
generated by connecting all the points determined by the
copy numbers in all the samples in an increasing order.
Since data on IHC grading as percent positive cells were
available on some of the samples, the correlation between
the IHC grading and the mRNA copy number was deter-
mined both in the original scale and in logarithmic trans-
formations scale using S-PLUS software.
Results
We have undertaken the current study to determine ERα
mRNA copy numbers in breast cancer tissues that were
positive and negative by two conventional methods of
assaying ERα protein, IHC and estrogen binding. The
rational for undertaking this study is that once we estab-
lish a threshold value in IHC negative tissues, then the
molecular assay could be applied in clinical laboratories
in the place of currently used IHC assay for determining
the status of ERα for prognostic and therapeutic purposes.
Our rational for establishing a cut off value is that any
patient who expresses above the cut off level could be
selected as a candidate for anti-estrogen therapies and
could be considered to have good prognosis.
We first profiled ERα mRNA copy numbers in 70 samples
positive by IHC, 43 negative by IHC, 33 positive by estro-
gen binding assay and 20 negative by estrogen binding
assay. The data are presented in Tables 1, 3, 2 and 4 respec-
tively. A box plot drawn for the copy numbers (logarithm
base 2 scale) in the four groups (positive and negative by
IHC and by estrogen binding assay) using S-PLUS soft-
ware is shown in Figure 1.
We next compared the quantitative data on mRNA copy
numbers among samples as described below. 1) We tested
whether the two conventional assays, the IHC and estro-
gen binding assays, correlate in terms of mRNA copyBMC Cancer 2007, 7:56 http://www.biomedcentral.com/1471-2407/7/56
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Table 1: ERα mRNA copy numbers in breast cancer tissues that were positive by IHC assay
# Grading by IHC (Percent of positive cells) ERα mRNA copy numbers per 1010 mRNA copies of GAPDH
11 0 0 1 . 5 0 e 8
21 0 0 6 . 5 0 e 6
31 0 0 1 . 3 3 e 8
41 0 0 1 . 0 0 e 8
51 0 0 3 . 0 0 e 8
61 0 0 2 . 2 0 e 7
71 0 0 2 . 5 0 e 7
81 0 0 6 . 5 0 e 8
91 0 0 2 . 0 0 e 5
10 99 2.25e8
11 98 1.33e8
12 98 7.14e7
13 98 4.50e8
14 97 4.50e8
15 95 8.00e7
16 91 2.06e8
17 90 5.71e7
18 90 2.50e8
19 90 3.80e7
20 90 2.08e8
21 90 4.50e7
22 90 8.50e7
23 90 2.50e6
24 90 1.88e8
25 90 1.80e7
26 90 1.25e8
27 90 2.86 e7
28 90 1.00 e8
29 90 3.00e7
30 90 4.17e6
31 90 3.75e8
32 90 8.50 e6
33 90 1.70e8
34 90 1.13e6
35 90 2.00e7BMC Cancer 2007, 7:56 http://www.biomedcentral.com/1471-2407/7/56
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36 90 3.00e7
37 90 5.00e7
38 90 4.25e7
39 80 2.86e7
40 80 2.50e6
41 80 2.83e7
42 80 4.88e7
43 60 3.25e7
44 60 2.00e6
45 40 1.00e6
46 40 1.35e8
47 30 5.00e8
48 20 8.00e7
49 *+ 2.06e7
50 *+ 6.06e7
51 *+ 4.0e7
52 *+ 8.0e7
53 *+ 5.0e6
54 *+ 2.06e7
55 *+ 3.06e7
56 *+ 4.06e8
57 *+ 6.06e7
58 *+ 1.06e6
59 *+ 4.06e8
60 *+ 1.06e6
61 *+ 8.0e6
62 *+ 2.0e6
63 *+ 3.0e7
64 *+ 2.0e8
65 *+ 1.0e6
66 *+ 7.0e6
67 *+ 2.0e7
68 *+ 4.0e7
69 *+ 8.0e6
70 *+ 9.0e6
* These samples were collected at the time when the practice was to grade the samples as just Positive or Negative but no numerical scorings were 
given.
Table 1: ERα mRNA copy numbers in breast cancer tissues that were positive by IHC assay (Continued)BMC Cancer 2007, 7:56 http://www.biomedcentral.com/1471-2407/7/56
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Table 2: ERα mRNA copy numbers in breast cancer tissues that were graded as positive by estrogen binding assay
#E R α by ligand binding ERα mRNA copy numbers per 1010 mRNA copies of GAPDH
1+ 9 e 5
2+ 5 e 7
3+ 3 e 7
4+ 4 e 7
5+ 2 e 7
6+ 6 e 5
7+ 4 e 6
8+ 4 e 8
9+ 2 e 7
10 + 2e7
11 + 1e7
12 + 1e7
13 + 1e8
14 + 1e7
15 + 4e5
16 + 4e6
17 + 4e7
18 + 1e6
19 + 4e7
20 + 4e8
21 + 6e7
22 + 2e8
23 + 5e7
24 + 4e7
25 + 1e6
26 + 3e7
27 + 3e7
28 + 3e6
29 + 2e8
30 + 2e7
31 + 1e8
32 + 3e8
33 + 5e7BMC Cancer 2007, 7:56 http://www.biomedcentral.com/1471-2407/7/56
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numbers in 70 and 33 positive tissues (Tables 1 and 2
respectively) using Wilcoxon-rank-sum test and standard
two-sample t-tests. By these two tests, we did not find sig-
nificant differences in the ERα mRNA copy numbers in
samples that were ERα positive by IHC and estrogen bind-
ing assays (p > 0.28 by both tests). 2) We also compared
the mRNA copy numbers in 43 samples negative by IHC
with 20 samples negative by estrogen binding assay and
did not find significant differences (Tables 3 and 4 respec-
tively) (p > 0.25 by the above two tests). However, 3) we
found significant differences in mRNA copy numbers in
the breast tumors that were IHC positive from those
which were IHC negative (Tables 1 and 3 respectively) (p
= 1.3e-6 by standard two-sample t-test and p = 2.7e-18 by
Wilcoxon-rank-sum test). And 4) we also found signifi-
cant differences in the samples that were positive and neg-
ative by estrogen binding assay (Tables 2 and 4
respectively) (p = 7.6e-3 by standard two-sample t-test
and p = 3.6e-7 by Wilcoxon-rank-sum test).
After establishing that ERα-positive tissues express signifi-
cantly higher levels of mRNA copy numbers compared to
negative tumor samples, we next determined the maxi-
mum level of expression in ERα-negative samples using
Table 3: ERα mRNA copy numbers in breast cancer tissues that were negative by IHC
# Grading by IHC ERα mRNA copy numbers per 1010 mRNA copies of GAPDH
1 - 1.25e6
2 - 1.25e6
3 - 1.00e5
4 - 3.75e6
5 - 8.00e5
6 - 2.00e6
7 - 3.00e5
8 - 2.50e6
9 - 2.50e5
10 - 6.25e4
11 - 1.67 e6
12 - 5.00e4
13 - 5.00e5
14 - 1.75e5
15 - 4.17e6
16 - 2.50e5
17 - 2.65e6
18 - 2.50e6
19 - 1.25e5
20 - 1.17e4
21 - 9.00e5
22 - 3.75e5
23 - 6.00e3
24 - 1.50e5
25 - 3.75e4
26 - 2.67e5
27 - 3.20e5
28 - 1.67e5
29 - 1.40e6
30 - 4.00e6
31 - 3.00e4
32 - 3.00e5
33 - 1.00e6
34 - 1.25e8
35 - 3.33e6
36 - 8.00e7
37 - 7.50e6
38 - 9.00e7
39 - 5.00e6
40 - 3.00e8
41 - 1.17e5
42 - 5.00e4
43 - 1.00e6BMC Cancer 2007, 7:56 http://www.biomedcentral.com/1471-2407/7/56
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CART program. By using this program, we found the max-
imum level of expression of mRNA copy numbers/cut-off
value to be 5 × 106 per 1010copies of GAPDH mRNA. Of
the total 106 positive (70 by IHC and 33 by estrogen bind-
ing assay) samples in our study, 83 samples showed
higher level of expression than 5 × 106 copies per 1010 cop-
ies of GAPDH. It is possible that the samples that showed
less than the above cut off value copy numbers could be
due to false positivity by the above methods. In a total of
63 negative samples (43 by IHC and 20 by estrogen bind-
ing assay) only 6 samples showed higher expression than
5 × 106 copies per 1010GAPDH copies. It is also possible
that the samples that showed higher than the cut off copy
numbers could be false negative. The OR (Odds Ratio) in
the two groups is about 39.4, an extremely high OR value.
The counts of the ERα-positive (80, 23) and ERα-negative
(6, 66) in the two groups produce a chi-square value of
88.2544 with 1 degree of freedom, which is consistent
with our T-test and Wilcoxon-rank-sum test results.
We applied the above cut off value and determined the
Sensitivity (percentage of samples that showed higher
copy numbers than the cut off value of 5 × 106 copies per
1010 GAPDH copies in IHC positive tissues) and Specifi-
city (percentage of samples that showed less than 5 × 106
copies per 1010 GAPDH copies in IHC negative tissues)
and the values obtained were 0.81 and 0.90 respectively.
We also determined Receiver Operating Characteristics
using S-PLUS software and the ROC curve generated is
shown in Figure 2. The area under the ROC curve,
0.89675, shows that the molecular assay clearly distin-
guishes the positives by IHC or estrogen binding from the
negative tissues.
Since we have the grading score as percent positive cells
for about 50 samples (Table 1), we tested if a correlation
exits between the percent positive cells by IHC and the
mRNA copy numbers using S-PLUS software. We
obtained a correlation coefficient of 0.02. When we used
the logarithmic transformations scale, we obtained a cor-
relation coefficient of 0.037. These results indicated that
there is no correlation between the percent positive cells
and the level of ERα mRNA copy numbers. These observa-
tions could be due to qualitative nature of IHC assay. The
IHC data only show the number of positive cells but not
quantitative to determine the level of ERα expression. The
molecular assay based on RNA is quantitative to deter-
mine the level of ERα expression.
Discussion and conclusion
Previously ERα mRNA levels in immunohistochemically
positive and negative tissues were evaluated in breast can-
cer tissues by several groups using conventional RT PCR.
Cullen et al [17] determined mRNA levels by conven-
tional PCR in 107 breast cancer tissues. They reported that
ERα mRNA was more frequently detected in ERα protein
positive tissues than ERα protein negative tissues. Jarza-
bek et al [18] studied ERα mRNA levels and protein levels
in 41 primary breast cancer tissues. They reported the
presence of ERα mRNA in all the tissues, where as the pro-
tein was present only in 70% of tumor tissues by Western
blotting and 67% showed positive by immunohistochem-
istry. They concluded that lack of ERα protein is not due
Table 4: ERα mRNA copy numbers in breast cancer tissues that were negative by estrogen binding assay
#E R α by ligand binding ERα mRNA copy numbers per 1010 mRNA copies of GAPDH
1- 1 . 6 e 5
2- 2 . 8 e 5
3- 5 . 6 e 5
4- 2 . 5 e 5
5- 3 . 2 e 5
6- 2 . 8 e 5
7- 1 . 2 e 5
8- 3 . 3 e 5
9- 2 . 5 e 5
10 - 1.5e6
11 - 2.7e6
12 - 1.0e6
13 - 2.0e7
14 - 1.0e6
15 - 9.5e5
16 - 2.1e6
17 - 6.0e5
18 - 1.0e6
19 - 1.1e6
20 - 7.7e5BMC Cancer 2007, 7:56 http://www.biomedcentral.com/1471-2407/7/56
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to lack of ERα gene expression or methylation of its pro-
moter, but may be due to post-transcriptional or post-
translational mechanisms. Alkarain et al [19] reported the
presence of ERα mRNA in immunohistochemically ERα-
negative tissues. However, none of the above studies has
evaluated the threshold levels of ERα mRNA levels in
immunohistochemically negative tissues or those nega-
tive by ligand binding assays. Our quantitative analysis of
ERα mRNA copy numbers demonstrate that breast cancer
tissues that are negative by both IHC and ligand binding
express significant levels of ERα mRNA. The reasons why
the mRNA is not translated to detectable protein are not
clear. Our previous studies on ERβ mRNA copy numbers
[9] in breast cancer tissues have shown that at the 5 × 106
copies per 1010 mRNA copies of GAPDH levels ERβ pro-
tein is translated. It is possible that either ERα mRNA is
not translated or the translated protein is degraded to
undetectable levels in these tissues.
The results and the analysis presented above clearly dem-
onstrate that the ERα positive tissues by IHC or estrogen
binding assay express significantly higher mRNA copy
numbers than 5 × 106 copies per 1010 GAPDH copies. An
extremely high Odds Ratio, high sensitivity and specificity
demonstrate that the molecular assay could be used in the
place of currently used IHC in the clinical laboratories.
Based on our data above any patient who has more than
5 × 106 copies per 1010 GAPDH copies in her tumor tissue
could be considered positive for ERα, could be selected for
anti-estrogen therapies and considered to have good prog-
nosis. However, the above described approach has some
limitations in that it needs to be verified on a defined set
of biopsy samples and with reference to another house
keeping gene. Therefore, the results should be interpreted
with caution and undoubtedly will require confirmation
by a larger prospective multi-centered clinical study with
a more accurate design to bring the technology to the
A Box plot drawn for the ERα mRNA copy numbers (logarithm base 2 scale) in the four groups (positive and negative by IHC  and by estrogen binding assay) using S-PLUS software is shown Figure 1
A Box plot drawn for the ERα mRNA copy numbers (logarithm base 2 scale) in the four groups (positive and negative by IHC 
and by estrogen binding assay) using S-PLUS software is shown.
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clinic. The current study is a first step in that direction. We
expect that the cost effective, extremely sensitive, high
though-put molecular assay which requires only a few
cancer cells could be an assay of choice to replace IHC in
clinical labs for determining ERα status in breast cancer
tissues once established in a multi-centered prospective
clinical study.
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